Abiomed’s Impella Cardiac Pump Needs PMA Study, FDA Panel Says
This article was originally published in The Gray Sheet
Better data is needed in the form of a PMA study to assess the safety and effectiveness of Abiomed’s flagship Impella 2.5 blood pump, advisory panel recommends.
You may also be interested in...
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
Chart updating FDA’s progress and decisions in classifying the final set of preamendment devices.
Circulatory System Devices panel recommends either class II or class III designations for external counter-pulsating devices and intra-aortic balloon pumps, depending on the indication.